A539 및 NCI-H460 인체 폐암세포의 증식 및 apoptosis 유도에 미치는 가미삼기보폐탕의 영향

키워드

참고문헌 (73)

1. Kelly, K., "The role of targeted agents in adjuvant therapy for non-small cell lung cancer", Clin Cancer Res, 11, pp.5027~5029 (2005)
2. Kiernan, P.D., "A pragmatic and successful approach to treating nonsmall-cell lung carcinoma", AORN J, 80, pp.840~857 (2004)
3. Raez, L.E., "Chemotherapy for advanced non-small-cell lung cancer", Clin Adv Hematol Oncol, 2, pp.173~178 (2004)
4. Gajra, A., "Impact of tumor size on survival in stage IA non-small cell lung cancer: a case for subdividing stage IA disease", Lung Cancer, 42, pp.51~57 (2003)
5. 대한결핵 및 호흡기학회, "호흡기학", pp.602~605 (2004), 군자출판사
6. 서울대학교 의과대학 내과학교실, "내과학", pp.32~ (2005), 고려의학
7. Yang, C.H., "Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer", Br J Cancer, 86, pp.190~195 (2002)
8. Scarpati, M.D., "Gemcitabine and small cell lung cancer", Lung Cancer, 34, pp.313~314 (2001)
9. Worden, F.P., "Therapeutic advances in small cell lung cancer", Expert Opin Investig Drugs, 9, pp.565~579 (2000)
10. Massarelli, E., "Use of novel second-line targeted therapies in non-small cell lung cancer", Semin Oncol, 33, pp.9~16 (2006)
11. Steinke, K., "Lung tumors", Recent Results Cancer Res, pp.107~122 (2006)
12. Fabian, D., "Apoptotic processes during mammalian preimplantation development", Theriogenology, 64, pp.221~231 (2005)
13. 윤창렬, "대전", pp.768~ (2002), 난경연구집성
14. "경리. 중국고대의방진본비본전집 33권. 전국도서관문헌축미복제중심; 2004; p. 359", ~ (2004)
15. 李東垣, "東垣醫集", pp.419~ (1993), 인민위생출판사
16. 陳無擇, "陳無擇三因方", pp.10~, 大中國圖書公司
17. 李梴, "醫學入門", pp.212~213 (1980), 남산당
18. 허만규, "인체폐암세포 NCI-H460 및 A549의 apoptosis 유발에 미치는 參_補肺湯의 영향", 대한한방내과학회지, 28(3), pp.473~491 (2007), 대한한방내과학회
19. 강락원, "길경 수용액 추출물에 의한 인체 폐암세포의 성장억제 기전 연구", 동의생리병리학회지, 17(1), pp.182~188 (2003), 대한동의병리학회
20. 이성열, "桔梗이 人體 肺癌細胞에 미치는 영향에 대한 실험적 연구", 동의생리병리학회지, 17(4), pp.1019~1030 (2003), 대한동의병리학회
21. 한의과대학본초학편찬위원회, "본초학", pp.499~500 (2006), 영림사
22. Fabian, D., "Apoptotic processes during mammalian preimplantation development", Theriogenology, 64, pp.221~231 (2005)
23. Levesque, A.A., "p53-based cancer therapies: Is defective p53 the Achilles heel of the tumor?", Carcinogenesis, 28, pp.13~20 (2007)
24. Harris, S.L., "The p53 pathway: positive and negative feedback loops", Oncogene, 24, pp.2899~2908 (2005)
25. Robles, A.I., "The p53 network in lung carcinogenesis", Oncogene, 21, pp.6898~6907 (2002)
26. Sherr, C.J., "The Pezcoller lecture: cancer cell cycles revisited", Cancer Res, 60, pp.3689~3695 (2000)
27. Bode, A.M., "Post-translational modification of p53 in tumorigenesis", Nat Rev Cancer, 4, pp.793~805 (2004)
28. Xu, Y., "Regulation of p53 responses by post- translational modifications", Cell Death Differ, 10, pp.400~403 (2003)
29. el-Deiry, W.S., "Vogelstein, WAF1", CIP1 is induced in p53-mediated G1 arrest and apoptosis, 1994, pp.54, 1169~1174
30. Sato, T., "p53-independent expression of p21(CIP1", WAF1) in plasmacytic cells during G(2) cell cycle arrest induced by Actinobacillus actinomycetemcomitans cytolethal distending toxin, 2002, pp.70, 528~534
31. Ding, Z., "The investigational new drug XK469 induces G(2)-M cell cycle arrest by p53-dependent and -independent pathways", Clin Cancer Res, 7, pp.3336~3342 (2001)
32. Brugarolas, J., "Inhibition of cyclin-dependent kinase 2 by p21 is necessary for retinoblastoma protein-mediated G1 arrest after gamma-irradiation", Proc Natl Acad Sci USA, 96, pp.1002~1007 (1999)
33. Bunz, F., "Requirement for p53 and p21 to sustain G2 arrest after DNA damage", Science, 282, pp.1497~1501 (1998)
34. Chang, B.D., "Effects of p21Waf1", Cip1, Proc Natl Acad Sci USA, pp.2000, 97[DOI]
35. Suzuki, A., "Procaspase 3", p21 complex formation to resist fas-mediated cell death is initiated as a result of the phosphorylation of p21 by protein kinase A, 2000, pp.7, 721~728
36. Hengst, L., "Complete inhibition of Cdk", cyclin by one molecule of p21(Cip1), 1998, pp.12, 3882~3888
37. Yang, H.L., "p21 Waf-1 (Cip-1) enhances apoptosis induced by manumycin and paclitaxel in anaplastic thyroid cancer cells", J Clin Endocrinol Metab, 88, pp.763~772 (2003)
38. Qiao, L., "Cyclin kinase inhibitor p21 potentiates bile acid-induced apoptosis in hepatocytes that is dependent on p53", Hepatology, 36, pp.39~48 (2002)
39. Baek, S.J., "Expression of NAG-1, a transforming growth factor-beta superfamily member, by troglitazone requires the early growth response gene EGR-1", J Biol Chem, 279, pp.6883~6892 (2004)
40. Calogero, A., "The early growth response gene EGR-1 behaves as a suppressor gene that is down-regulated independent of ARF", Mdm2 but not p53 alterations in fresh human gliomas, 2001, pp.7, 2788~2798
41. de Belle, I., "p53 and Egr-1 additively suppress transformed growth in HT1080 cells but Egr-1 counteracts p53- dependent apoptosis", Oncogene, 18, pp.3633~3642 (1999)
42. Liu, C., "Suppression of growth and transformation and induction of apoptosis by EGR-1", Cancer Gene Ther, 5, pp.3~28 (1998)
43. Huang, R.P., "Decreased Egr-1 expression in human, mouse and rat mammary cells and tissues correlates with tumor formation", Int J Cancer, 72, pp.102~109 (1997)
44. Virolle, T., "The Egr-1 transcription factor directly activates PTEN during irradiation-induced signalling", Nat Cell Biol, 3, pp.1124~1128 (2001)
45. Huang, R.P., "Egr-1 negatively regulates human tumor cell growth via the DNA-binding domain", Cancer Res, 55, pp.5054~5062 (1995)
46. Baek, S.J., "Resveratrol enhances the expression of non-steroidal anti-inflammatory drug-activated gene (NAG-1) by increasing the expression of p53", Carcinogenesis, 23, pp.425~434 (2002)
47. Baek, S.J., "Cyclooxygenase inhibitors regulate the expression of a TGF-ß superfamily member that has proapoptotic and antitumorigenic activities", Mol Pharmacol, 59, pp.901~908 (2001)
48. Tan, M., "PTGF-ß, a type beta transforming growth factor (TGF-ß) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-ß signaling pathway", Proc Natl Acad Sci USA, 97, pp.109~114 (2000)
49. Li, P.X., "downstream mediator of the growth arrest and apoptotic response of tumor cells to DNA damage and p53 overexpression", J Biol Chem, 275, pp.20127~20135 (2000)
50. FitzGerald, G.A., "COX-2 and beyond: Approaches to prostaglandin inhibition in human disease", Nat Rev Drug Discov, 2, pp.879~890 (2003)
51. Ke, J., "Role of NF-kappaB in TNF-alpha-induced COX-2 expression in synovial fibroblasts from human TMJ", J Dent Res, 86, pp.363~367 (2007)
52. Wu, R., "Up-regulation of Rac1 by epidermal growth factor mediates COX-2 expression in recurrent respiratory papillomas", Mol Med, 13, pp.143~150 (2007)
53. Balzary, R.W., "Lipopolysaccharide induces epithelium- and prostaglandin E(2)- dependent relaxation of mouse isolated trachea through activation of cyclooxygenase (COX)-1 and COX-2", J Pharmacol Exp Ther, 317, pp.806~812 (2006)
54. Soloff, M.S., "In situ analysis of interleukin-1-induced transcription of cox-2 and il-8 in cultured human myometrial cells", Endocrinology, 145, pp.1248~1254 (2004)
55. Chen, C., "Review of the Cox model", J Toxicol Environ Health A, 61, pp.521~523 (2000)
56. Dempke, W., "Cyclooxygenase-2: a novel target for cancer chemotherapy?", J Cancer Res Clin Oncol, 127, pp.411~417 (2001)
57. Brown, J.R., "Cyclooxygenase as a target in lung cancer", Clin Cancer Res, 10, pp.4266~4299 (2004)
58. Koki, A., "Cyclooxygenase-2 in human pathological disease", Adv Exp Med Biol, 507, pp.177~184 (2002)
59. Surh, Y.J., "Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-κB activation", Mutat Res, 480, pp.243~268 (2001)
60. Yamamoto, Y., "Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer", J Clin Invest, 107, pp.135~142 (2001)
61. Sawaoka, H., "Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo", Lab Invest, 79, pp.1469~1477 (1999)
62. Chen, K.H., "Tangeretin suppresses IL-1beta-induced cyclooxygenase (COX)-2 expression through inhibition of p38 MAPK, JNK, and AKT activation in human lung carcinoma cells", Biochem Pharmacol, 73, pp.215~227 (2007)
63. Chen, P., "Involvement of PKC, p38 MAPK and AP-2 in IL-1beta- induced expression of cyclooxygenase-2 in human pulmonary epithelial cells", Respirology, 11, pp.18~23 (2006)
64. Nieminen, R., "Inhibitors of mitogen- activated protein kinases downregulate COX-2 expression in human chondrocytes", Mediators Inflamm, 5, pp.249~255 (2005)
65. Rosch, S., "Prostaglandin E2 induces cyclooxygenase-2 expression in human nonpigmented ciliary epithelial cells through activation of p38 and p42", 44 mitogen-activated protein kinases, 2005, pp.338, 1171~1178
66. Cho, J.W., "Curcumin inhibits the expression of COX-2 in UVB-irradiated human keratinocytes (HaCaT) by inhibiting activation of AP-1: p38 MAP kinase and JNK as potential upstream targets", Exp Mol Med, 37, pp.186~192 (2005)
67. Poole, J.C., "Activity, function, and gene regulation of the catalytic subunit of telomerase (hTERT)", Gene, 269, pp.1~12 (2001)
68. Weinrich, S.L., "Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT", Nat Genet, 17, pp.498~502 (1997)
69. Shay, J.W., "A survey of telomerase activity in human cancer", Eur J Cancer, 33, pp.787~791 (1997)
70. Kyo, S., "Complex regulatory mechanisms of telomerase activity in normal and cancer cells: How can we apply them for cancer therapy", Oncogene, 21, pp.688~697 (2002)
71. Narayan, S., "DNA damage-induced cell cycle checkpoints involve both p53-dependent and -independent pathways: role of telomere repeat binding factor 2", Br J Cancer, 85, pp.898~901 (2001)
72. Vaziri, H., "ATM- dependent telomere loss in aging human diploid fibroblasts and DNA damage lead to the post-translational activation of p53 protein involving poly(ADP-ribose) polymerase", EMBO J, 16, pp.6018~6033 (1997)
73. Cerni, C., "Telomeres, telomerase, and myc", Mutat Res, 462, pp.31~47 (2000)

관련 논문AI추천